Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00113295 · ClinicalTrials.gov registry record · Phase 4

Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder

A Phase 4 study of Anxiety Disorder, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 4
Development phase
50
Enrollment target
2
Study locations

NCT00113295: Completed Phase 4 study of Anxiety Disorder, sponsored by Massachusetts General Hospital.

NCT00113295 is a Phase 4 study of Anxiety Disorder that has completed, run by Massachusetts General Hospital. The registered enrollment target is 50 participants, below the 423-participant average among 20 other Anxiety Disorder trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00113295, a Phase 4 study of Anxiety Disorder, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 4
Development phase
50 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to examine the safety and efficacy of quetiapine for generalized anxiety disorder patients who remain symptomatic despite treatment with paroxetine CR.

Conditions Studied

Anxiety Disorder

Interventions

  • DRUG Placebo
  • DRUG Quetiapine
  • DRUG Continued Paroxetine CR

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2004-02
Est. Completion 2007-11
Phase Phase 4

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00113295

The ClinicalTrials.gov registry entry for NCT00113295 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 423-participant average among 20 other Anxiety Disorder trials with a reported enrollment target (88% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Anxiety Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00113295 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00113295 about?

NCT00113295 is a clinical study titled "Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder". The purpose of this study is to examine the safety and efficacy of quetiapine for generalized anxiety disorder patients who remain symptomatic despite treatment with paroxetine CR.

What is the current status of trial NCT00113295?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2004-02. Estimated completion is 2007-11.

What conditions does trial NCT00113295 study?

This clinical trial studies the following conditions: Anxiety Disorder.

What interventions are being tested in trial NCT00113295?

The interventions under investigation include: Placebo (DRUG), Quetiapine (DRUG), Continued Paroxetine CR (DRUG).

Who is sponsoring clinical trial NCT00113295?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00113295 being conducted?

This trial has 2 study locations across Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anxiety Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Anxiety Disorder

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.